RIBONUCLEASE ACTIVITY AS POSSIBLE DIAGNOSTIC AND PROGNOSIS MARKER OF PROSTATE CANCER

Shlyakhovenko V.O.¹, Samoylenko O.A.¹, Verbinenko A.V.¹, Stakhovsky E.O.²

• ¹R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
• ²National Cancer Institute, Kyiv, Ukraine

Aim: to investigate the relationship between the level of ribonuclease (RNase) activity in the prostate tumor, in the biological fluids and the clinical and pathological features of the neoplastic process of patients with prostate cancer (PCa). Evaluate the possibility of their use as diagnostic and prognostic criteria for personalized assessment of the development and course of PCa and for the development of new schemes of personalized treatment (prediction of the sensitivity of malignant tumor to antitumor agents). Object and methods: the study used samples of tumor tissue, peripheral blood and urine of 120 patients with different stages of PCa (T1-T4) (mean age was 65.0 ± 7.88 years) and 30 patients with prostatic intraepithelial invasion (PIN) (mean age was 60,2 ± 3.6 years). The RNase activity was determined by zymogram using electrophoresis in 15% polyacrylamide gel. Results: the gradual decrease of the RNases activity in prostate tissue with the progression of PCa was found (from 460.8 ± 20.3AU to 103.5 ± 22.9 AU). At the same time, there is an increase in the level of prostate-specific antigen (PSA) in the blood plasma of patients and the degree of the spread of the process, according to the Gleason scale. It was found that erythrocytes cytosol and urine show the highest enzymatic activity in donors. Conclusions: in tumor tissue a gradual decrease of the RNase activity during the progressing of tumor growth was found. In erythrocytes cytosol of patients with PCa a decrease of the RNase activity was observed in comparison to donors. An increase of the RNase activity in the blood plasma of PCa patients with the Gleason scale (≥7) was found. The obtained data show that the RNase activity may be additional biomarker for the diagnosis and choosing tactics for personalized treatment of PCa patients.